These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37940790)
21. Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine. Hirosawa K; Fujioka H; Morinaga G; Fukami T; Ishiguro N; Kishimoto W; Nakase H; Mizuguchi H; Nakajima M Drug Metab Dispos; 2023 Dec; 51(12):1569-1577. PubMed ID: 37722844 [TBL] [Abstract][Full Text] [Related]
22. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia. Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking. Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129 [TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Ebert B; Kisiela M; Wsól V; Maser E Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737 [TBL] [Abstract][Full Text] [Related]
25. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086 [TBL] [Abstract][Full Text] [Related]
26. Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo-keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics. Marinović MA; Petri ET; Grbović LM; Vasiljević BR; Jovanović-Šanta SS; Bekić SS; Ćelić AS Mol Inform; 2022 Oct; 41(10):e2100256. PubMed ID: 35393780 [TBL] [Abstract][Full Text] [Related]
27. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies. Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib. Büküm N; Novotná E; Morell A; Želazková J; Laštovičková L; Čermáková L; Portillo R; Solich P; Wsól V Biochem Pharmacol; 2021 Oct; 192():114710. PubMed ID: 34339712 [TBL] [Abstract][Full Text] [Related]
29. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. O'connor T; Ireland LS; Harrison DJ; Hayes JD Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of human aldose reductase-like protein (AKR1B10) by α- and γ-mangostins, major components of pericarps of mangosteen. Soda M; Endo S; Matsunaga T; Zhao HT; El-Kabbani O; Iinuma M; Yamamura K; Hara A Biol Pharm Bull; 2012; 35(11):2075-80. PubMed ID: 23123477 [TBL] [Abstract][Full Text] [Related]
31. Tolrestat acts atypically as a competitive inhibitor of the thermostable aldo-keto reductase Tm1743 from Thermotoga maritima. Zhang C; Min Z; Liu X; Wang C; Wang Z; Shen J; Tang W; Zhang X; Liu D; Xu X FEBS Lett; 2020 Feb; 594(3):564-580. PubMed ID: 31573681 [TBL] [Abstract][Full Text] [Related]
32. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde. Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680 [TBL] [Abstract][Full Text] [Related]
33. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995 [TBL] [Abstract][Full Text] [Related]
34. The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10. Seliger JM; Misuri L; Maser E; Hintzpeter J J Enzyme Inhib Med Chem; 2018 Dec; 33(1):607-614. PubMed ID: 29532688 [TBL] [Abstract][Full Text] [Related]
35. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling. Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108 [TBL] [Abstract][Full Text] [Related]
36. Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10. Shi L; Guo S; Zhang S; Gao X; Liu A; Wang Q; Zhang T; Zhang Y; Wen A Eur J Pharmacol; 2020 Sep; 883():173167. PubMed ID: 32485245 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids. Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway. Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753 [TBL] [Abstract][Full Text] [Related]